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Abstract
Background: Antithrombotics are frequently prescribed for patients with a limited life expectancy. In the last phase
of life, when treatment is primarily focused on optimizing patients’ quality of life, the use of antithrombotics should
be reconsidered.
Methods: We performed a secondary analysis of a retrospective review of 180 medical records of patients who had
died of a malignant or non-malignant disease, at home, in a hospice or in a hospital, in the Netherlands. All
medication prescriptions and clinical notes of patients using antithrombotics in the last three months of life were
reviewed manually. We subsequently developed case vignettes based on a purposive sample, with variation in
setting, age, gender, type of medication, and underlying disease.
Results: In total 60% (n=108) of patients had used antithrombotics in the last three months of life. Of all patients
using antithrombotics 33.3 % died at home, 21.3 % in a hospice and 45.4 % in a hospital. In total, 157
antithrombotic prescriptions were registered; 30 prescriptions of vitamin K antagonists, 60 of heparins, and 66 of
platelet aggregation inhibitors. Of 51 patients using heparins, 32 only received a prophylactic dose. In 75.9 % of
patients antithrombotics were continued until the last week before death. Case vignettes suggest that inability to
swallow, bleeding complications or the dying phase were important factors in making decisions about the use of
antithrombotics.
Conclusions: Antithrombotics in patients with a life limiting disease are often continued until shortly before death.
Clinical guidance may support physicians to reconsider (dis)continuation of antithrombotics and discuss this with
the patient.
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Background
Antithrombotics are frequently prescribed to patients
with a life-limiting disease [1–7]. They mainly involve
platelet aggregation inhibitors (PAIs) or anticoagulants.
PAIs are mainly prescribed for primary or secondary
prevention of arterial thrombosis, such as non-
cardiogenic ischemic stroke [8], and for coronary and
peripheral arterial disease (PAD) [9, 10]. Anticoagulants
include three types: 1) heparins, 2) vitamin K antagonists
(VKA), and 3) non-VKA oral anticoagulants (NOACs).
The majority of patients with a life-limiting disease use
anticoagulants for the prevention of thromboembolic
events due to atrial fibrillation (AF) [11]. Other main
reasons for using anticoagulants in the last phase of life
are primary or secondary prevention and treatment (ter-
tiary prevention) of venous thromboembolism (VTE)
and prevention of thromboembolic events after heart
valve replacement.
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Most patients have been taking antithrombotics for a
long period of time before their life expectancy becomes
limited due to an illness. The number of patients still
using antithrombotics at the end of life may vary de-
pending on the population, setting and country. Of 16,
896 patients with lung cancer who were admitted to a
hospice, 9.2 % used an anticoagulant, of whom about
80 % used a VKA and the remaining 20 % a low-
molecular-weight heparin (LMWH) [12]. In a retrospect-
ive study, 1141 patients who were admitted for acute
care in a hospital were discharged to hospice care [11].
Of these patients, 64 % had a cardiovascular disease, and
about 20 % suffered from cerebrovascular disease. Only
77 (6,7 %) patients had a prescription for antithrombotic
therapy upon their discharge to hospice care. The main
indications for antithrombotic use in this study were AF
(41.6 %), history of stroke (31.2 %), deep venous throm-
bosis (DVT) or pulmonary embolism (PE) (11.7 %) or
heart valve replacement (10.4 %). Various other studies
have shown that up to half of all patients with an ad-
vanced illness and frail elderly patients continue to use
antithrombotics in the last weeks of life [1–4]. A large
cohort study in Sweden in older adults showed that anti-
thrombotic use was similar (about 50 %) 12 months and
one month before death. Most of these patients used a
PAI (44 %), about 7 % a VKA and 2–5 % a LMWH [1].
About 20–30 % of patients in a hospice or frail elderly
still use PAIs [5–7].
In the last phase of life, when treatment is primarily
focused on optimizing patients’ quality of life, the use of
antithrombotics should be reconsidered since the risk
benefit ratio may change [13–17]. Clinically apparent
VTE occurs in as many as 10 % of cancer patients [18],
whereas almost 10 % of patients experience a clinically
relevant bleeding at the end of life, with about one fifth
of these bleedings contributing to death [15].
Comprehensive guidelines for (dis)continuation of
antithrombotics in patients with a life-limiting disease
are not available [19, 20]. The lack of evidence on out-
comes of (dis)continuation of medication at the end of
life and the complexity of clinical situations may lead to
dilemmas in decision-making regarding antithrombotics.
Moreover, insufficient awareness promotes continuation
of potentially inappropriate medication in the last phase
of life [21]. This may unnecessarily result in suboptimal
quality of life and quality of death for patients with ma-
lignant and non-malignant life-limiting diseases.
Thromboembolic as well as bleeding complications may
lead to acute severe distressing situations, for patients,
family and health care professionals.
In this paper, we report on a chart review study of the
prescription of antithrombotics for patients with a life
expectancy of less than three months staying at home, in
a hospice or a hospital. The aim of this study was to gain
more insight into management of antithrombotics in pa-
tients with a life-limiting disease and to conduct an in-
depth analysis of the (dis)continuation of antithrombo-
tics in patients in the last three months of life.
Methods
Design
We conducted a secondary analysis of a retrospective
chart review within the MEDIcation management in the
LAST phase of life (MEDILAST) project. MEDILAST is
a multicenter mixed methods research project with the
aim of understanding current medication use in the last
phase of life. The project was carried out by Erasmus
University Medical Center in Rotterdam, Radboud Uni-
versity Medical Center in Nijmegen, and Amsterdam
University Medical Center Vrije Universiteit in
Amsterdam, all in the Netherlands. The study design,
data collection and results of overall medication use in
the last week of life have been described previously [22].
Data collection
We collected a convenience sample of medical records
of patients who had died at home, in a hospice or in a
hospital. We aimed to include 60 medical records in
each region of influence of the participating centers
(Rotterdam, Nijmegen and Amsterdam). In each region
20 medical records were drawn from the home, hospice
and hospital setting. We asked physicians to select their
two or three most recent cases of patients who had died
expectedly from a chronic condition. For each region,
we randomly selected a number of family physician
practices and approached them by telephone. In each re-
gion, the hospice setting was represented by a high care
hospice, where a palliative care physician is at all times
available for consultation. For the hospital setting, we in-
cluded records from patients who had died in an aca-
demic or peripheral hospital, at a cardiology, geriatrics,
neurology, oncology or pulmonology ward.
Following acceptance to participate in the study, three
physician researchers (second, third and fourth author)
visited the clinical wards and practices to collect the
data. A structured electronic form (MS Access 2013)
was used to retrieve the information from the medical
records. Demographics included age at the time of
death, place of death and primary and comorbid diagno-
ses. Information about medication use in the last three
months of life was registered, which included medication
generic names, administration routes, doses and start
and stop dates. The medical records were manually
screened for information about the decision making on
medication use. The indication for the antithrombotic
was derived from clinical notes as well as primary and
secondary diagnoses. All methods were carried out in
accordance with relevant guidelines and regulations for
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data collection from medical records [23]. All medica-
tion prescriptions of patients using antithrombotics were
reviewed manually and of each patient using antithrom-
botics a case description was made including decision-
making regarding the medication. Subsequently, case
descriptions were selected by purposive sampling, with
variation in setting, age, gender, medication, underlying
disease and medical history and were rewritten as illus-
trative case vignettes.
The Medical Ethics Review Committee of the
Amsterdam University Medical Center Vrije Universiteit
approved the study protocol (ref. no. 2013/47). Approval
in all other participating centers was obtained from the
board of directors or relevant authority before data
collection.
Data analysis
Medications were coded using the World Health
Organization Center for Drug Statistics Methodology’s
Anatomical Therapeutic Chemical (ATC) classification
at the level of therapeutic subgroup (second), pharmaco-
logical subgroup (third), medication chemical subgroup
(fourth) and chemical substance (fifth) [24]. IBM SPSS
Statistics 26 (IBM Corporation, 2019) was used to obtain
descriptive statistics.
Results
A total of 180 medical records were reviewed in this
study. One patient died within 24 h of admission to a
hospice and was not included in the analysis. In the
last three months of life, 60% (n=108) of patients had
used antithrombotics. Table 1 shows the characteris-
tics of patients using antithrombotics per setting. Of
all patients using antithrombotics 46.3 % were female;
33.3 % died at home, 21.3 % in a hospice and 45.4 %
in a hospital. The period of time for which medica-
tion use was registered ranged from one day to three
months (mean 43.8 days, median 24 days). In total,
157 antithrombotic prescriptions were registered (see
Table 2). In 82 patients (75.9 %), antithrombotics were
continued until the last week before death. Case vi-
gnettes of patients using antithrombotics are pre-
sented in Tables 3, 4 and 5.
Vitamin K antagonists
In total, 30 prescriptions of VKAs were registered in 29
patients, of whom 41.4 % died at home, 10.3 % in a hos-
pice and 48.3 % in a hospital. Only one patient used
phenprocoumon, all other prescriptions involved aceno-
coumarol (n = 29). In one patient acenocoumarol was
stopped because of an intervention and restarted. The
indications for the VKA varied from atrial fibrillation
(Table 3, case 1 and 2), cardiac failure, cardiac valve dis-
ease, PE, DVT, to PAD (Table 3, case 3) and previous
cerebrovascular accident (CVA) or transient ischemic at-
tack (TIA) (Table 3, case 1). In total, 23 patients stopped
using the VKA before death, of whom 17 patients less
Table 1 Patient characteristics per setting
Characteristics Setting Total






Age, mean (SD) 77.7 (13.2) 73.4 (10.7) 74.8 (12.1) 75.5 (12.2)
Female gender, No. (%) 20 (55.6) 8 (34.8) 22 (44.9) 50 (46.3)



























Table 2 Antithrombotic prescriptions













acetylsalicylic acid 30 19.1
carbasalate calcium 27 17.2
Other fondaparinux 1 0.6
Total 157 100
VKA vitamin K antagonist, PAI platelet aggregation inhibitor
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than one week before death (range 0–33 days, mean 5.2
days, median 2 days). In four patients bleeding complica-
tions were registered: painful hematoma in the flank (92
yrs, AF, TIA and urosepsis), fatal subdural hematoma (87
yrs, previous myocardial infarction, cardiac valve disease
and renal insufficiency, combined with PAI), hematomas
due to frequent falls (Table 3, case 2) and lung bleeding in
lung cancer (Table 3, case 3). In some cases the VKA was
stopped because of a prolonged INR (78 yrs, AF, cardiac
failure, PAD and dialysis; 99 yrs, AF, cardiac failure and
renal insufficiency). Other reasons for discontinuation that
were mentioned were difficulty to swallow medication,
drowsiness (Table 3, case 1), interaction with fluconazole,
clinical deterioration, short life expectancy and patient’s re-
quest. In one patient suffering from an ileus the VKA was
switched to therapeutic LMWH.
Heparins
In total, 60 prescriptions were registered in 51 patients,
of whom 13.7 % died at home, 23.5 % in a hospice and
62.7 % in a hospital. Thirty-two patients received
LMWH only in a prophylactic dose because of an acute
Table 3 Vitamin K antagonist case vignettes
Vitamin K antagonist
1. 82-year-old woman at home with pancreatic carcinoma.
Atrial fibrillation, arterial hypertension, TIA, NIDDM
Acenocoumarol (VKA)
Comedication: amitriptyline retard 1dd 50 mg, amlodipine 1dd 5 mg,
atorvastatin 10 mg, bisoprolol 1dd 2.5 mg, candesartan 1dd 16 mg,
metformin 1dd 500 mg, pantoprazole 1dd 40 mg, temazepam 1dd
10 mg a.n.
Seventeen days before death metformin is increased to 2dd 500 mg
because of an increase in HbA1c. Ten days before death she is drowsy
and nauseous. Metformin is stopped and glimepiride 1dd 2 mg is
started. Amitriptyline, amlodipine and atorvastatin is stopped. The
candesartan is decreased to 1dd 8 mg. Three days later she has a
glucose of 1.8 mmol/L (32.4 mg/dL) and glimepiride is stopped. Three
days later metformin is restarted at 2dd 250 mg because of a glucose of
8.6 mmol/l (154.8 mg/dL).
She deteriorates, and three days later she is unconscious. All medication
(including the acenocoumarol) is stopped and morphine suppository
4dd 20 mg is started. She dies the following day.
2. 95-year-old woman at home with arterial hypertension, atrial fibrilla-
tion, COPD and dementia.
Acenocoumarol (VKA)
Comedication: cholecalciferol 1dd 800 IE, furosemide 1dd 80 mg,
digoxin 1dd 0.125 mg, losartan 1dd 25 mg, temazepam 1dd 10 mg a.n.
She suffers from dyspnea and therefore the furosemide is increased
with 40 mg/day extra for ten days. She frequently falls and suffers from
hematomas. The acenocoumarol is stopped. Two days later she has
fever and dyspnea. All other medication is stopped, she receives some
morphine and midazolam and passes away.
3. 67-year-old man at home with metastatic lung carcinoma. Previous
history of arterial hypertension, peripheral arterial disease and NIDDM.
Acenocoumarol (VKA)
Comedication: bisacodyl suppository 1dd 10 mg p.r.n., ibuprofen 1d
600 mg, metformin 1dd 500 mg, midazolam s.c. 15 mg p.r.n. (in case of
lung bleeding), macrogol/electrolytes 1dd 1 sachet, oxycodone IR 6 dd
5 mg p.r.n., pantoprazole 1dd 40 mg, paracetamol 4dd 1000 mg,
simvastatin 1dd 40 mg, zolpidem 1dd 10 mg a.n. p.r.n.
Because of a pneumonia amoxicillin 3 dd 500 mg for a week and
prednisone 3dd 10 mg for two weeks is started. He receives
metoclopramide 3dd 10 mg rectally as needed because of vomiting
due to a gastroenteritis. A month later he suffers from a dry cough and
ipratropium inhaler 4dd and codeine 3dd 20 mg as needed is started,
with limited effect. A week later he is admitted because of hemoptysis
and the acenocoumarol is stopped. Back home oxazepam 1dd 10 mg as
needed is started in case of anxiety. He gradually deteriorates and dies a
month later.
TIA transient ischemic attack, NIDDM non-insulin dependent diabetes mellitus,
VKA vitamin K antagonist, COPD chronic obstructive pulmonary disease, a.n.
ante noctem, p.r.n. pro re nata (as needed), s.c. subcutaneous
Table 4 Heparins case vignettes
Heparins
1. 87-year-old woman with an intracerebral tumor and secondary epi-
lepsy for which she receives comfort care. Further hypothyroidism and
dyslipidemia.
Acetylsalicylic acid 1dd 80 mg
Comedication: dexamethasone 2dd 2 mg, phenytoin 2dd 150 mg,
gemfibrozil 1dd 600 mg, levetiracetam 2dd 1000 mg, pantoprazole 1dd
40 mg, paracetamol 3dd 1000 mg p.r.n., temazepam 1dd 10 mg a.n.,
thyroxine 1dd 0.025 mg
She is admitted at the hospital because of persisting partial convulsions.
In between she is lucid and well-oriented. Clonazepam 2dd 0.5 mg is
added and levetiracetam is gradually increased up to 2dd 1750 mg. Val-
proic acid 2dd 500 mg is added, and clonazepam increased up to 3dd
2 mg. Midazolam s.c. is titrated as needed 0.5-5 mg. Nadroparin 1dd
2850 IE is started six days after admission because of bedriddenness.
She develops an expressive aphasia and agitation. Haloperidol 1 mg as
needed is added. Two and a half weeks after admission she turns un-
conscious. All medication is continued until death.
2. 53-year-old man at home with pancreatic carcinoma and IDDM.
Medication: amlodipine/valsartan 1dd 10/160 mg, diclofenac 2dd 75 mg,
fentanyl transdermal 25 mcgr/h, haloperidol 2dd 1 mg, insulin pump
s.c., omeprazole 1dd 40 mg, paracetamol 4dd 1000 mg,
natriumlaurylsulfoacetate/natriumcitrate/sorbitol rectal p.r.n.
Because of increasing pain diclofenac is increased to 3dd 75 mg and
fentanyl nasal 50 mcg/dose as needed is added. After two weeks the
fentanyl nasal is increased to 100 mcg/dose as needed. One week later
tinzaparin 1dd 18,000 IE is started because of clinical signs of a deep
venous thrombosis on the calf. Diclofenac and fentanyl is stopped and a
morphine pump is started s.c. 5 mg/h and bolus 4 mg s.c. as needed.
Amlodipine/valsartan is stopped because of low blood pressure. A week
later palliative sedation is started with midazolam pump s.c. up to
15 mg/h. The oral medication is stopped, tinzaparin is continued. He
passes away two days later.
3. 77-year-old woman with metastasized esophageal carcinoma and
deep venous thrombosis is admitted to a hospice.
Previous history: arterial hypertension, genital cancer, urinary tract
infection.
Nadroparin (Fraxiparine forte) 1dd 15,200 IE
Comedication at admission: fentanyl transdermal 12 mcgr/h every 3
days, hydrochlorothiazide 1dd 12,5 mg, macrogol/electrolytes 1dd 1
sachet every two days, oxazepam 3dd 20 mg p.r.n., oxycodone IR 6dd
5 mg p.r.n., paracetamol 4dd 1000 mg p.r.n., temazepam 1dd 20 mg a.n.
Two days after admission the hydrochlorothiazide is stopped, and
haloperidol 1dd 1 mg and nitrofurantoin 4dd 50 mg is started because
of signs of a delirium and cystitis. Fentanyl is switched to morphine
retard 2dd 20 mg orally and morphine 5 mg 6dd orally as needed,
because of pain and dyspnea. After two weeks morphine retard is
increased to 2dd 30 mg because of dyspnea. After one week morphine
15 mg/24 h, haloperidol 2,5 mg/24 h and midazolam 42 mg/24 h is
started s.c. because of refractory dyspnea and delirium. Oral medication
is discontinued. She dies one day later. Nadroparin was continued until
death.
IDDM insulin dependent diabetes mellitus, a.n. ante noctem, p.r.n. pro re nata
(as needed), s.c. subcutaneous
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medical condition or bedriddenness (Table 4, case 1). In
three patients the prescribed heparin was changed to a
different formulation. In two patients the dose was ad-
justed from a prophylactic dose to a therapeutic dose,
because of newly diagnosed PE in one case and un-
known condition in another case. In one patient with
cardiac failure a heparin pump was discontinued, be-
cause of the decision to discontinue life-sustaining treat-
ments, and switched to prophylactic LMWH. In several
patients a heparin was started a few weeks before death
(e.g. Table 4, case 1 and 2). Even in an unconscious or
sedated patient the heparin was continued (Table 4, case
1, 2 and 3). A patient with colon carcinoma and previous
PE received therapeutic dose LMWH until death, despite
frequent nose bleeding. In total, 31 patients stopped
using the heparins before death, of whom 21 patients
less than one week before death (range 0–59 days, mean
5.5 days, median 1 day). Some specific reasons were
mentioned for discontinuation. In two patients because
of a bleeding (LMWH prophylaxis in laryngeal carcin-
oma and prophylaxis in a patient with an intracranial
tumor) and once as family wanted unnecessary medica-
tion to be discontinued
Platelet aggregation inhibitors
In total, 66 prescriptions of platelet aggregation inhibi-
tors were registered in 55 patients, of whom 36.4 % died
at home, 18.2 % at a hospice and 45.5 % in a hospital.
Two of these patients used two PAIs (i.e. acetylsalicylic
acid and clopidogrel). Other patients used a PAI and
LMWH (n = 11) or VKA (n = 5), or two PAIs and a
LMWH (n = 3) or VKA (n = 2). In three patients a PAI
was switched to a different formulation in the last weeks
of life. A patient suffering from sepsis, and previous his-
tory CVA, PAD, rheumatoid arthritis, diabetes and
hypertension, used acetylsalicylic acid, clopidogrel and
fondaparinux until start of palliative sedation. In total,
39 patients stopped using the PAI before death, of whom
29 patients less than one week before death (range 0–76
days, mean 5.9 days, median 1 day). In several patients
the PAI was discontinued because of refusal by the pa-
tient, difficulty (Table 5, case 2) or discomfort to swal-
low medication. A 83-year old patient with a previous
ischemic CVA and hypertension used acetylsalicylic acid
and dipyridamole and died of a massive intracranial
bleeding. In some patients the PAI was continued des-
pite discontinuation of other oral preventive medications
(Table 5, case 1). Table 5 case 3 presents a case vignette
of a patient with lung cancer with cerebral metastases
using a PAI because of intermittent claudication, in
which the PAI is continued until death.
Discussion
In this chart review study we found that a large number
of patients used antithrombotics in the last three
months, weeks or days of their lives. PAIs and heparins
were more frequently prescribed than VKA, and anti-
thrombotic prescriptions were more frequent in patients
who died in a hospital. The case vignettes reveal exam-
ples of what happens in clinical practice on the patient
level and show that antithrombotics are continued until
death, irrespective of (dis)continuation of other medica-
tions in the last weeks of life. Antithrombotics may be of
questionable benefit due to changes in goals of care in
the last phase of life and the benefit-harm balance of this
medication.
In our study, we found a relatively high prevalence of
antithrombotic use (60 %) compared to previous studies
[1–3, 5]. We do not have a plausible explanation for this.
As in the other studies, the antithrombotics in our study
Table 5 Platelet aggregation inhibitor case vignettes
Platelet aggregation inhibitors
1. 86-year-old woman at home with heart failure, previous myocardial
infarction, rectal blood loss and rheumatoid arthritis.
Carbasalate calcium 1dd 100 mg
Comedication: atenolol 1dd 100 mg, lisinopril 1dd 20 mg, loperamide
2dd 2 mg p.r.n., paracetamol 3dd 1000 mg, simvastatin 1dd 40 mg
She receives nitrofurantoin 4dd 50 mg for five days because of a urinary
tract infection. A month later she develops a pneumonia for which she
receives doxycycline 1dd 100 mg for a week. After three days
amoxicillin/clavulanic acid 3dd 500/125 mg is started for five days
because of clinical deterioration. With the patient and her daughter it is
decided not to admit to the hospital in case of further deterioration.
She gradually deteriorates, has difficulty to swallow the medication.
Atenolol, lisinopril, loperamide and simvastatin are stopped. She receives
haloperidol droplets if needed in case of agitation. She passes away
after more than a month. The paracetamol and carbasalate calcium
were continued until death.
2. 87-year-old man at home with leukemia. Previous myocardial infarc-
tion, prostate carcinoma and NIDDM.
Acetylsalicylic acid 1dd 80 mg
Comedication: citalopram 1dd 20 mg, diltiazem 1dd 300 mg,
esomeprazole 1dd 40 mg, furosemide 1dd 40 mg
He gradually deteriorates. Oxazepam as needed 2dd 5 mg is started
because of agitation two and half months before death. Two months
later paracetamol suppository as needed 1000 mg and fentanyl 12 mcg/
h transdermal is started because of pain. He is unable to swallow his
medication and so all oral medication is stopped. Morphine s.c. as
needed is started for pain and dyspnea. He passes away 6 days later.
3. 66-year-old man admitted to a hospice because of lung carcinoma
with cerebral metastases. Previous history of intermittent claudication,
colon carcinoma and benign prostate hypertrophy.
Carbasalate calcium 1dd 100 mg
Comedication at admission: dexamethasone 1dd 3 mg, esomeprazole
1dd 40 mg, macrogol/electrolytes 1dd 1 p.r.n., metformin 2dd 1000 mg,
paracetamol 4dd 1000 mg p.r.n., spironolactone 1dd 25 mg
As needed midazolam and morphine s.c. is ordered in case of massive
hemoptysis or brain herniation. After a week the dexamethasone is
increased because of headache and nausea. Insulin is given in case of
high blood glucose levels. Symptoms decrease and in a month the
dexamethasone can be decreased to 1dd 1 mg. However, a few days
later symptoms recur, dexamethasone is increased to 1dd 3 mg and
after 2.5 weeks to 1dd 8 mg. A month later he further deteriorates. He
receives morphine s.c. 5 mg as needed for dyspnea and pain and passes
away two days later. All oral medication was continued until death.
NIDDM non-insulin dependent diabetes mellitus, p.r.n. pro re nata (as needed),
s.c. subcutaneous
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mainly involved PAIs. The second most frequently used
antithrombotic in patients with a life-limiting disease is
VKAs or LMHWs depending on the population studied
[1, 4, 5, 12]. In our study a relatively high number of pa-
tients used LMWHs, with about half of the prescriptions
concerning a prophylactic dose.
Dilemmas in decision-making
We hypothesize that physicians may be reluctant to dis-
continue antithrombotics due to complex clinical di-
lemmas. On the one hand, the medical assessment of
potential benefits of (dis)continuing antithrombotics and
minimizing the risk of adverse events is complicated and
hampered by uncertainties. On the other hand, it is a chal-
lenge to discuss the use of antithrombotics with the pa-
tient and to reach a shared decision, taking into account
benefits versus risks, patients’ quality of life and perceived
medication burden. Studies into dilemmas in decision-
making regarding antithrombotics in patients with a lim-
ited life expectancy, mostly concern anticoagulation in
cancer patients and deprescribing of medication in frail
elderly. Dilemmas in decision-making regarding antith-
rombotics in patients with a limited life expectancy
reflected by the case vignettes and described in literature
are multiple [25–32]. Examples of these dilemmas are:
when to (dis)continue anticoagulants in patients with AF
and cancer (Table 3, case 1), old age, frailty (Table 3, case
2) or risk of falls; when to (dis)continue PAIs in patients
with cardiovascular disease combined with or without
cancer (Table 5); when (not) to start or stop thrombopro-
phylaxis (e.g. bedriddenness) (Table 4, case 1); when (not)
to start or stop anticoagulants in cancer patients with
symptomatic or incidental VTE (Table 4, case 2 and 3);
how to balance the risk of bleeding versus PE in patients
with lung carcinoma (Table 3, case 3); how to manage
antithrombotics in patients with an increased risk of
bleeding due to comorbidity (e.g. thrombocytopenia);
which PAI or (dose of) anticoagulant is most appropriate.
Cancer associated thrombosis
Noble and colleagues especially contributed to this field
with their studies into cancer associated thrombosis
(CAT) and mention that according to guidelines indefinite
anticoagulation should be considered for patients with
cancer and VTE [33–35]. Particularly, stomach and pan-
creas carcinoma are associated with a very high risk of
CAT, and lymphoma, lung, gynecologic, bladder, testicular
and renal carcinoma with a high risk [36]. However,
though the majority of CAT patients with metastatic dis-
ease remain anticoagulated up to or within days of death,
it appears that anticoagulation in this situation confers a
significant bleeding risk without additional benefit of pre-
venting VTE symptoms [33]. The OncPal deprescribing
guideline is the only guideline for deprescribing of
medication in oncological patients, and merely addresses
the use of aspirin with the advice to discontinue it in case
of primary prevention [37].
(De)prescribing in elderly
Guidelines or tools for medication management in pa-
tients with a limited life expectancy due to non-malignant
disease mainly involve those for elderly with advanced
age, dementia or multimorbidity [38–40]. The Beers cri-
teria and STOPP/START are some of the frequently used
tools. The Beers criteria regarding antithrombotics advice
to use aspirin for primary prevention with caution in
adults above 70, prasugrel with caution above 75 years; to
avoid oral short acting dipyridamole; and prescribe dabi-
gatran and rivaroxaban for treatment of VTE or AF with
caution in adults above 75 years; and avoid or reduce the
dose of NOACs in the case of reduced renal function [41].
The STOPP/START give recommendations for adults
above 65 years, mainly to avoid any antithrombotic in case
of a significant bleeding risk; combine aspirin and clopido-
grel only in selected cases; not to combine PAIs with VKA
or NOACs; to discontinue VKA or NOACs after more
than 6 respectively 12 months in patients without con-
tinuing provoking risk factors suffering a first DVT or PE
[42]. Unfortunately, there is still a lack of standardization
in assessment of medication appropriateness in patients
with a limited life expectancy and a need for an approach
that is specifically designed and validated for populations
with a life-limiting illness [39].
Need for clinical guidance
In this chart review study, we found that discontinuation of
antithrombotics seems to be done mainly in reaction to a
bleeding, inability to swallow or patient’s request. In a pre-
vious study we found that there is substantial variation in
physicians’ opinions regarding the use of anticoagulants in
patients with a limited life expectancy and they lack evi-
dence about the risks and benefits of stopping anticoagu-
lants in decision-making [43]. Which decision physicians
eventually made seemed largely dependent on the choice of
the patient [43]. Physicians need more evidence-based guid-
ance to proactively discuss the use of antithrombotics and
direction to come to a decision consistent with the patient’s
goals and preferences. Patients with a life-limiting disease
often prefer to reduce the number of medications they have
to take, but they have concerns about the negative conse-
quences or uncertainty of stopping the medication [44], risk
of bleeding or thromboembolic complications [45]. Thus,
clinical guidance may facilitate more rational and patient
centered decisions. Therefore, we propose that a first step
towards clinical guidance could be considered in practice to
guide medical advice for antithrombotics and shared
decision-making in patients with a life expectancy of less
than three months (Supplement, with Figs. 1 and 2).
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Limitations
Our study involved a secondary analysis of data from a
retrospective chart review study. Results might be influ-
enced by selection bias and discrepancy between the reg-
istered prescriptions and actual use. Not in all cases the
decision-making process was clear due to insufficient de-
scription in the clinical notes. Whereas the indication of
antithrombotic use is not explicitly recorded in medical
records, in most cases it was derived from clinical notes
as well as patients’ primary and secondary diagnoses.
Further, possibly relevant comorbid conditions, like
renal function and coagulation disorders, were often not
specifically registered with laboratory results, especially
in patients in hospices or at home. Our sample of pa-
tients is relatively out of date concerning the use of
NOACs. None of the patients used a NOAC. Specific
considerations regarding NOACs were not represented,
such as the relative ease in use or inferior efficacy in cer-
tain patient populations. However, the dilemmas regard-
ing (dis)continuation are considered to be comparable to
VKAs and therapeutic dose LMWHs. It was not the
scope of this study to elaborate on the choice of anti-
coagulant for therapeutic use. Guidelines for the man-
agement of AF [46], VTE [47] and CAT [48] do give
recommendations on the choice of anticoagulant, and
many studies focus on this in complex patients with
CAT [29, 49], AF in cancer patients [50] and in elderly
patients [41, 51].
Conclusions
A large number of patients with a life limiting disease
still use antithrombotics in the last three months and
even days of their lives. PAIs and heparins were more
frequently prescribed than VKA, and antithrombotic
prescriptions were more frequent in hospitalized pa-
tients. Dilemmas in decision-making regarding antith-
rombotics in patients with a limited life expectancy are
reflected by case vignettes, and it seems that decision-
making regarding antithrombotics is mainly a reactive
process. The impact of possible thromboembolic and
bleeding complications on quality of life and quality of
death demand for a proactive decision-making regarding
antithrombotics. Clinical guidance may support physi-
cians to proactively give medical advice regarding (dis)-
continuation of antithrombotics and consecutively have
a shared-decision making discussion with the patient.
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